IL104041A - Pharmaceutical compositions comprising an hmg-CoA reductase inhibitor compound and method for their preparation - Google Patents

Pharmaceutical compositions comprising an hmg-CoA reductase inhibitor compound and method for their preparation

Info

Publication number: IL104041A
Authority: IL; Israel
Prior art keywords: carbonate; sodium; composition; hmg; alkaline medium
Prior art date: 1991-12-12

Application number

IL10404192A

Other languages

English (en)

Other versions

IL104041A0 (en

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-12

Filing date

1992-12-10

Publication date

1998-12-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36808687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL104041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-12-10 Application filed by Novartis Ag filed Critical Novartis Ag

1993-05-13 Publication of IL104041A0 publication Critical patent/IL104041A0/xx

1998-12-27 Publication of IL104041A publication Critical patent/IL104041A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 40
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 14
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 14
238000000034 method Methods 0.000 title claims description 22
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title description 2
239000000203 mixture Substances 0.000 claims abstract description 106
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims abstract description 31
-1 fluvastatin sodium Chemical class 0.000 claims abstract description 27
239000007864 aqueous solution Substances 0.000 claims abstract description 10
239000006185 dispersion Substances 0.000 claims abstract description 10
229960000868 fluvastatin sodium Drugs 0.000 claims abstract description 9
230000000087 stabilizing effect Effects 0.000 claims abstract description 7
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 38
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 20
239000008108 microcrystalline cellulose Substances 0.000 claims description 20
229940016286 microcrystalline cellulose Drugs 0.000 claims description 20
229910000019 calcium carbonate Inorganic materials 0.000 claims description 19
239000008186 active pharmaceutical agent Substances 0.000 claims description 16
229940088679 drug related substance Drugs 0.000 claims description 16
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 15
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 12
150000005323 carbonate salts Chemical class 0.000 claims description 12
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 11
229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
125000001041 indolyl group Chemical group 0.000 claims description 5
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
125000000168 pyrrolyl group Chemical group 0.000 claims description 4
239000011734 sodium Substances 0.000 claims description 4
229910052708 sodium Inorganic materials 0.000 claims description 4
150000001768 cations Chemical class 0.000 claims description 3
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 3
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 3
125000003226 pyrazolyl group Chemical group 0.000 claims description 3
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
125000001544 thienyl group Chemical group 0.000 claims description 3
XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims description 2
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 2
125000002098 pyridazinyl group Chemical group 0.000 claims description 2
235000015424 sodium Nutrition 0.000 claims description 2
239000008203 oral pharmaceutical composition Substances 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
229940083542 sodium Drugs 0.000 claims 1
239000007892 solid unit dosage form Substances 0.000 claims 1
125000003831 tetrazolyl group Chemical group 0.000 claims 1
239000002552 dosage form Substances 0.000 abstract description 13
230000015556 catabolic process Effects 0.000 abstract description 6
238000006731 degradation reaction Methods 0.000 abstract description 6
159000000000 sodium salts Chemical class 0.000 description 30
229960003765 fluvastatin Drugs 0.000 description 22
239000003814 drug Substances 0.000 description 18
229940079593 drug Drugs 0.000 description 17
239000003826 tablet Substances 0.000 description 17
235000010216 calcium carbonate Nutrition 0.000 description 14
239000000945 filler Substances 0.000 description 14
239000002245 particle Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
238000009472 formulation Methods 0.000 description 11
239000007888 film coating Substances 0.000 description 10
238000009501 film coating Methods 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
229920000881 Modified starch Polymers 0.000 description 8
238000003860 storage Methods 0.000 description 8
238000001035 drying Methods 0.000 description 7
238000009505 enteric coating Methods 0.000 description 7
239000002702 enteric coating Substances 0.000 description 7
239000008187 granular material Substances 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
238000002156 mixing Methods 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 5
239000000463 material Substances 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
235000002639 sodium chloride Nutrition 0.000 description 5
238000005550 wet granulation Methods 0.000 description 5
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 4
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 4
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
239000002610 basifying agent Substances 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
239000008188 pellet Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229960003975 potassium Drugs 0.000 description 4
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000001665 trituration Methods 0.000 description 4
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
125000002541 furyl group Chemical group 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
239000008101 lactose Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000008044 alkali metal hydroxides Chemical class 0.000 description 2
230000000181 anti-adherent effect Effects 0.000 description 2
239000003911 antiadherent Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000920 calcium hydroxide Substances 0.000 description 2
229910001861 calcium hydroxide Inorganic materials 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
239000004744 fabric Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229910052806 inorganic carbonate Inorganic materials 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
239000000347 magnesium hydroxide Substances 0.000 description 2
229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000003605 opacifier Substances 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical group C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010034960 Photophobia Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
206010057040 Temperature intolerance Diseases 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
AYVGBNGTBQLJBG-UHFFFAOYSA-N [3-(hydroxymethyl)cyclopentyl]methanol Chemical compound OCC1CCC(CO)C1 AYVGBNGTBQLJBG-UHFFFAOYSA-N 0.000 description 1
GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical class [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940024548 aluminum oxide Drugs 0.000 description 1
JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 description 1
RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
239000002585 base Substances 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000011162 core material Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
229960002380 dibutyl phthalate Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
238000007905 drug manufacturing Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
YURNCBVQZBJDAJ-UHFFFAOYSA-N heptenoic acid group Chemical group C(C=CCCCC)(=O)O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
208000013469 light sensitivity Diseases 0.000 description 1
229960004018 magaldrate Drugs 0.000 description 1
QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
239000002370 magnesium bicarbonate Substances 0.000 description 1
235000014824 magnesium bicarbonate Nutrition 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910000406 trisodium phosphate Inorganic materials 0.000 description 1
235000019801 trisodium phosphate Nutrition 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL10404192A 1991-12-12 1992-12-10 Pharmaceutical compositions comprising an hmg-CoA reductase inhibitor compound and method for their preparation IL104041A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80566791A	1991-12-12	1991-12-12
CN93100650A CN1041794C (zh)	1991-12-12	1993-01-30	含有一种β－羟基－β－甲基戊二酸单酰辅酶A还原酶抑制剂的稳定的药物组合物

Publications (2)

Publication Number	Publication Date
IL104041A0 IL104041A0 (en)	1993-05-13
IL104041A true IL104041A (en)	1998-12-27

Family

ID=36808687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10404192A IL104041A (en)	1991-12-12	1992-12-10	Pharmaceutical compositions comprising an hmg-CoA reductase inhibitor compound and method for their preparation

Country Status (31)

Country	Link
US (1)	US5356896A (fr)
EP (1)	EP0547000B1 (fr)
JP (1)	JP2774037B2 (fr)
KR (1)	KR100253824B1 (fr)
CN (1)	CN1041794C (fr)
AT (1)	AT401870B (fr)
AU (1)	AU661075B2 (fr)
CA (1)	CA2085037C (fr)
CH (1)	CH684309A5 (fr)
CY (1)	CY1994A (fr)
CZ (1)	CZ287776B6 (fr)
DE (1)	DE4240430B4 (fr)
DK (1)	DK0547000T3 (fr)
ES (1)	ES2142819T3 (fr)
FI (1)	FI114284B (fr)
FR (1)	FR2684876B1 (fr)
GB (1)	GB2262229B (fr)
GR (1)	GR3032929T3 (fr)
HK (1)	HK25597A (fr)
HU (2)	HU9203780D0 (fr)
IL (1)	IL104041A (fr)
IT (1)	IT1256698B (fr)
LU (1)	LU88201A1 (fr)
MX (1)	MX9207152A (fr)
NO (1)	NO302099B1 (fr)
NZ (1)	NZ245421A (fr)
PT (1)	PT547000E (fr)
RO (1)	RO111542B1 (fr)
RU (1)	RU2121835C1 (fr)
SK (1)	SK281710B6 (fr)
ZA (1)	ZA929642B (fr)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6300361B1 (en) *	1990-07-25	2001-10-09	Novartis Ag	Stabilized pharmaceutical compositions comprising acid donors
DE4243279A1 (de) *	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
US5399356A (en) *	1994-03-24	1995-03-21	The Procter & Gamble Company	Process for making solid dose forms containing bismuth
RU2152209C1 (ru) *	1994-05-13	2000-07-10	Егис Гиогисзергуар Р.Т.	Гемфиброзил-содержащие фармацевтические композиции
EP0845039A2 (fr) *	1995-08-17	1998-06-03	The Regents Of The University Of California	Genes et proteines regulant la synthese du cholesterol
DK0814782T3 (da) *	1995-12-22	2002-12-16	Nissan Chemical Ind Ltd	Farmaceutisk præparat stabiliseret med et basisk middel
NZ330774A (en) *	1996-04-05	1999-06-29	Takeda Chemical Industries Ltd	Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
WO1997038960A1 (fr)	1996-04-16	1997-10-23	Takeda Chemical Industries, Ltd.	D-mannitol et sa preparation
JP3126683B2 (ja)	1996-04-16	2001-01-22	武田薬品工業株式会社	Ｄ−マンニトールおよびその製造法
DE69719755T2 (de) *	1996-06-24	2003-11-20	Novartis Ag, Basel	Polymorphe verbindungen
SE9603667D0 (sv) *	1996-10-08	1996-10-08	Astra Ab	Pharmaceutical compositions
SE9603668D0 (sv) *	1996-10-08	1996-10-08	Astra Ab	Pharmaceutical compositions
DE19725391A1 (de) *	1997-06-16	1998-12-17	Bayer Ag	Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren
US6465477B1 (en) *	1997-08-18	2002-10-15	Kowa Company, Ltd.	Stable pharmaceutical composition
US20060141036A1 (en) *	1997-12-12	2006-06-29	Andrx Labs Llc	HMG-CoA reductase inhibitor extended release formulation
US6235311B1 (en) *	1998-03-18	2001-05-22	Bristol-Myers Squibb Company	Pharmaceutical composition containing a combination of a statin and aspirin and method
US20010014352A1 (en)	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
US5997905A (en) *	1998-09-04	1999-12-07	Mcneil-Ppc	Preparation of pharmaceutically active particles
SI20070A (sl)	1998-09-18	2000-04-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Nove soli inhibitorjev HMG-CoA reduktaze
US20020169145A1 (en) *	1998-10-14	2002-11-14	Rajen Shah	Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
SK288117B6 (sk)	1998-11-20	2013-09-03	Skyepharma Canada Inc.	Rapidly dispersing solid dry therapeutic dosage form
TWI230618B (en) *	1998-12-15	2005-04-11	Gilead Sciences Inc	Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
SI20109A (sl) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
JP2002538202A (ja) *	1999-03-08	2002-11-12	メルクエンドカムパニーインコーポレーテッド	ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
US6569461B1 (en)	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1036563A1 (fr) *	1999-03-08	2000-09-20	MERCK & CO. INC.	Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
WO2000067737A2 (fr) *	1999-05-07	2000-11-16	The Brigham And Women's Hospital, Inc.	UTILISATION D'INHIBITEURS DE HMGCoA REDUCTASE POUR LA PREVENTION DE MALADIES DONT LA PATHOGENESE DEPEND D'UNE NEOFORMATION DE VAISSEAUX SANGUINS
CA2389973A1 (fr) *	1999-11-04	2001-05-10	Andrx Corporation	Methode de traitement de troubles lies au precurseur beta-amyloide
US20020107173A1 (en) *	1999-11-04	2002-08-08	Lawrence Friedhoff	Method of treating amyloid beta precursor disorders
GB0001621D0 (en) *	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
DE60138535D1 (de)	2000-02-04	2009-06-10	Children S Hospital Res Founda	Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
BR0109991A (pt) *	2000-04-11	2003-05-27	Sankyo Co	Composição farmacêutica
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
GB0011163D0 (en) *	2000-05-10	2000-06-28	Astrazeneca Ab	Chemical compound
CN1217930C (zh) *	2000-05-26	2005-09-07	西巴特殊化学品控股有限公司	吲哚衍生物的制备方法和该方法的中间体
US6806290B2 (en)	2000-06-09	2004-10-19	Lek Pharmaceuticals D.D.	Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SK16982002A3 (sk)	2000-06-09	2003-04-01	Lek Pharmaceuticals D. D.	Stabilizovaná farmaceuticky účinná kompozícia a liečivý prípravok túto kompozíciu obsahujúci
DE60041281D1 (de)	2000-06-09	2009-02-12	Lek Pharmaceuticals	Stabilisiertes arzneimittel und arzneizubereitung
US8586094B2 (en)	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
WO2002080762A1 (fr)	2001-04-06	2002-10-17	Medic4All Inc.	Systeme de surveillance physiologique destine a un dispositif informatique d'un sujet humain
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
GB0111077D0 (en)	2001-05-04	2001-06-27	Biochemie Gmbh	Organic compounds
CA2445712A1 (fr) *	2001-05-31	2002-12-05	Cellegy Pharmaceuticals, Inc.	Inhibiteurs d'influx calcique active par reserve, et leurs procedes d'utilisation
JP2005500307A (ja) *	2001-06-21	2005-01-06	アンドルックスファーマスーティカルズインコーポレーテッド	プラバスタチンを含む安定な徐放性薬剤組成物
ES2304140T3 (es) *	2001-08-03	2008-09-16	Ciba Holding Inc.	Formas cristalinas de sodio de fluvastatina.
EP1443928B1 (fr)	2001-10-16	2011-07-27	Sloan-Kettering Institute For Cancer Research	Traitement des maladies neurodegeneratives et du cancer du cerveau
US7183321B2 (en) *	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
AR038839A1 (es) *	2002-02-14	2005-01-26	Ranbaxy Lab Ltd	Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracion
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en)	2002-03-04	2006-12-12	Merck Hdac Research, Llc	Methods of treating mesothelioma with suberoylanilide hydroxamic acid
MXPA04008577A (es)	2002-03-04	2005-07-13	Aton Pharma Inc	Metodos para inducir diferenciacion terminal.
EP1496982A4 (fr) *	2002-04-16	2006-07-19	Merck & Co Inc	Formes solides de sels a activite tyrosine kinase
ES2375181T3 (es)	2002-05-09	2012-02-27	The Brigham And Women's Hospital, Inc.	1l 1rl-1 como un marcador de enfermedades cardiovasculares.
CA2385529A1 (fr) *	2002-05-21	2003-11-21	Bernard Charles Sherman	Formulations posologiques stables contenant de l'atorvastatin calcium
ES2315510T3 (es) *	2002-06-13	2009-04-01	Novartis Ag	Sales de calcio de estatinas derivadas del indol.
US20040006109A1 (en) *	2002-07-03	2004-01-08	Rajneesh Taneja	Liquid dosage forms of non-enterically coated acid-labile drugs
US20060019269A1 (en) *	2002-10-17	2006-01-26	Decode Genetics, Inc.	Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) *	2002-10-17	2008-11-27	Anna Helgadottir	Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20040198800A1 (en) *	2002-12-19	2004-10-07	Geoffrey Allan	Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003283769A1 (en)	2002-12-20	2004-07-14	Pfizer Products Inc.	Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
CA2510319A1 (fr) *	2002-12-20	2004-07-15	Thomas J. Smith	Compactage haute pression pour formulations pharmaceutiques
BRPI0408442A (pt) *	2003-03-17	2006-04-04	Japan Tobacco Inc	método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
TWI393560B (zh) *	2003-05-02	2013-04-21	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7166638B2 (en) *	2003-05-27	2007-01-23	Nicox S.A.	Statin derivatives
SG141430A1 (en)	2003-05-30	2008-04-28	Ranbaxy Lab Ltd	Substituted pyrrole derivatives and their use as hmg-co inhibitors
EP1790634A3 (fr) *	2003-06-18	2007-06-13	Teva Pharmaceutical Industries Ltd.	Forme cristalline de sodium de fluvastatine et ses procédés de préparation
JP2007077174A (ja) *	2003-06-25	2007-03-29	Novartis Ag	フルバスタチン含有錠剤
AU2004251439B2 (en) *	2003-06-25	2008-09-11	Novartis Ag	Tablet comprising fluvastatin and carmellose calcium
GB2404336A (en) *	2003-07-30	2005-02-02	Cipla Ltd	Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
CN1839114A (zh)	2003-08-21	2006-09-27	默克弗罗斯特加拿大有限公司	组织蛋白酶半胱氨酸蛋白酶抑制剂
EP1510208A1 (fr)	2003-08-22	2005-03-02	Fournier Laboratories Ireland Limited	Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
EP2428516A1 (fr)	2003-11-19	2012-03-14	Metabasis Therapeutics, Inc.	Nouvelles substances thyromimetiques contenant du phosphore
JP2007512347A (ja) *	2003-11-26	2007-05-17	デューク・ユニバーシティー	緑内障を予防するかまたは治療する方法
EP1702626B1 (fr)	2003-12-30	2011-11-30	Kowa Company, Ltd.	Procédé de criblage d'inhibiteurs gamma-sécrétase
US8163797B2 (en) *	2003-12-31	2012-04-24	Actavis Elizabeth Llc	Method of treating with stable pravastatin formulation
US20100216863A1 (en) *	2004-01-30	2010-08-26	Decode Genetics Ehf.	Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) *	2005-03-30	2012-04-17	Decode Genetics Ehf.	Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US7803838B2 (en) *	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
US20090042979A1 (en) *	2004-08-06	2009-02-12	Transform Pharmaceuticals Inc.	Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
WO2006017692A2 (fr) *	2004-08-06	2006-02-16	Transform Pharmaceuticals, Inc.	Nouvelles preparations de fenofibrate et methodes de traitement associees
KR20070038553A (ko) *	2004-08-06	2007-04-10	트렌스폼 파마수티컬스 인코퍼레이티드	신규한 스타틴 약제학적 조성물 및 관련된 치료방법
DE102004042139B4 (de) *	2004-08-31	2009-06-10	Aristocon Verwaltungs- Gmbh	Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
ES2439229T3 (es)	2004-10-06	2014-01-22	The Brigham And Women's Hospital, Inc.	Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
ES2255426B1 (es) *	2004-10-19	2007-08-16	Gp Pharm, S.A.	Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
WO2006062876A2 (fr)	2004-12-09	2006-06-15	Merck & Co., Inc.	Modulateurs du recepteur de l'oestrogene
CA2592605C (fr)	2004-12-27	2010-12-07	Eisai R&D Management Co., Ltd.	Methode de stabilisation d'un medicament contre la demence
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
NZ560386A (en) *	2005-01-31	2009-12-24	Mylan Lab Inc	Pharmaceutical composition comprising hydroxylated nebivolol
AU2006302797B2 (en)	2005-03-02	2012-02-02	Merck Canada Inc.	Composition for inhibition of cathepsin K
US20060229277A1 (en) *	2005-04-08	2006-10-12	Orbus Pharma, Inc.	Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
CA2604617C (fr) *	2005-04-28	2014-06-17	Eisai R&D Management Co., Ltd.	Composition renfermant une drogue contre la demence
ATE550019T1 (de)	2005-05-17	2012-04-15	Merck Sharp & Dohme	Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
NZ563759A (en)	2005-05-31	2010-06-25	Mylan Lab Inc	Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
AU2006329564A1 (en)	2005-07-11	2007-07-05	Pharmena North America Inc.	Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
WO2007016757A1 (fr) *	2005-08-05	2007-02-15	Orbus Pharma Inc.	Compositions pharmaceutiques a liberation prolongee, stabilisees, comprenant un inhibiteur de l'hmg-coa reductase
PE20070335A1 (es) *	2005-08-30	2007-04-21	Novartis Ag	Benzimidazoles sustituidos y metodos para su preparacion
US8119358B2 (en)	2005-10-11	2012-02-21	Tethys Bioscience, Inc.	Diabetes-related biomarkers and methods of use thereof
BRPI0618379A2 (pt)	2005-11-08	2011-08-30	Ranbaxy Lab Ltd	processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US20090247603A1 (en) *	2005-12-23	2009-10-01	Orbus Pharma, Inc.	Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1905424A3 (fr) *	2006-02-02	2008-04-30	Ranbaxy Laboratories Limited	Procédé de preparation d'une composition pharmaceutique comprenant des particules de statine stabilisées
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
JP2009527577A (ja) *	2006-02-24	2009-07-30	テバファーマシューティカルインダストリーズリミティド	フルバスタチンナトリウム医薬組成物
AR059838A1 (es) *	2006-03-14	2008-04-30	Ranbaxy Lab Ltd	Formulaciones para dosis estabilizantes de estatina
KR101464385B1 (ko)	2006-04-19	2014-11-21	노파르티스 아게	６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
CA2659082A1 (fr)	2006-06-07	2007-12-21	Tethys Bioscience, Inc.	Marqueurs associes a des evenements arterio-vasculaires et procedes d'utilisation de ces marqueurs
CA2787343C (fr)	2006-06-26	2016-08-02	Amgen Inc.	Compositions comprenant de la lcat modifiee et leur utilisation
WO2008026702A1 (fr)	2006-08-30	2008-03-06	Kyushu University, National University Corporation	Composition pharmaceutique contenant une nanoparticule de statine encapsulée
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
RU2487703C2 (ru) *	2006-09-26	2013-07-20	Новартис Аг	Фармацевтические композиции, включающие модулятор s1р
EP1923053A1 (fr) *	2006-09-27	2008-05-21	Novartis AG	Composition pharmaceutique comprenant de la nilotinib ou son sel
EP1911441A3 (fr) *	2006-10-11	2008-08-06	Lupin Limited	Formule de dosage pharmaceutique à couleur stable et à libération contrôlée d'inhibiteurs de réductase HMG-COA, sans agents alcalisants ou tampons
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080132560A1 (en) *	2006-11-21	2008-06-05	San-Laung Chow	Solid dispersion composition
US20110052688A1 (en) *	2006-11-21	2011-03-03	San-Laung Chow	Solid dispersion composition
BRPI0806245B1 (pt)	2007-01-10	2022-01-25	Msd Italia S.R.L.	Compostos de fórmula i e seus usos
CN101679266B (zh)	2007-03-01	2015-05-06	诺华股份有限公司	Pim激酶抑制剂及其应用方法
US20080249141A1 (en) *	2007-04-06	2008-10-09	Palepu Nageswara R	Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124120A1 (fr) *	2007-04-09	2008-10-16	Scidose, Llc	Combinaisons de statines et d'agent anti-obésité
US20080249156A1 (en) *	2007-04-09	2008-10-09	Palepu Nageswara R	Combinations of statins and anti-obesity agent and glitazones
TW200849035A (en)	2007-04-18	2008-12-16	Tethys Bioscience Inc	Diabetes-related biomarkers and methods of use thereof
AU2008254425A1 (en)	2007-05-21	2008-11-27	Novartis Ag	CSF-1R inhibitors, compositions, and methods of use
WO2009002495A1 (fr)	2007-06-27	2008-12-31	Merck & Co., Inc.	Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
SI2489731T1 (sl)	2007-07-26	2014-12-31	Amgen Inc. Patent Operations, M/S 28-2-C	Modificirani encimi lecitin-holesterol aciltransferaze
CN101945853B (zh)	2007-12-21	2014-08-20	配体药物公司	选择性雄激素受体调节剂(sarm)及其应用
EA024554B1 (ru) *	2008-06-27	2016-09-30	Крка, Товарна Здравил, Д.Д., Ново Место	Твердая лекарственная форма, содержащая розувастатин, и способ ее получения
EP2138165A1 (fr)	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique comportant de la statine
DK2306982T3 (en) *	2008-06-27	2015-04-20	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Pharmaceutical compositions of rosuvastatin calcium
WO2010093601A1 (fr)	2009-02-10	2010-08-19	Metabasis Therapeutics, Inc.	Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
JP2012096998A (ja) *	2009-02-27	2012-05-24	Kowa Co	安定なカプセル製剤及びその製造方法
EP2413932A4 (fr)	2009-04-01	2012-09-19	Merck Sharp & Dohme	Inhibiteurs de l'activité akt
TR200904341A2 (tr)	2009-06-03	2010-12-21	Bi̇lgi̇ç Mahmut	Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
CA2777043C (fr)	2009-10-14	2015-12-15	Schering Corporation	Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes
CN102665764A (zh) *	2009-12-22	2012-09-12	Fmc有限公司	可用作可再压实药物赋形剂的微晶纤维素和碳酸钙组合物
KR20120139723A (ko)	2010-02-01	2012-12-27	더 호스피탈 포 식 칠드런	재발협착증의 치료 및 예방을 위한 원격 허혈 처치
SG184353A1 (en)	2010-03-31	2012-11-29	Hospital For Sick Children	Use of remote ischemic conditioning to improve outcome after myocardial infarction
JP2013523349A (ja)	2010-04-08	2013-06-17	ザ・ホスピタル・フォー・シック・チルドレン	外傷性損傷に対する遠隔虚血コンディショニングの使用
US8372877B2 (en)	2010-04-16	2013-02-12	Cumberland Pharmaceuticals	Stabilized statin formulations
TR201009397A2 (tr)	2010-11-11	2012-05-21	Bi̇lgi̇ç Mahmut	Rosuvastatin içeren farmasötik bileşimler.
EP2584903B1 (fr)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8609138B2 (en)	2010-06-30	2013-12-17	Mochida Pharmaceutical Co., Ltd.	ω3 fatty acid compound preparation
CN103068980B (zh)	2010-08-02	2017-04-05	瑟纳治疗公司	使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
EP3459533A1 (fr)	2010-08-04	2019-03-27	Grünenthal GmbH	Forme galénique pharmaceutique comprenant 6'-fluoro-(n-méthyl- or n,n-diméthyl-)-4-phényl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine pour le traitement de la douleur nociceptive
RU2745848C2 (ru)	2010-08-17	2021-04-01	Сирна Терапьютикс, Инк.	ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012027331A1 (fr)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
EP2613782B1 (fr)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
US20130210860A1 (en)	2010-10-06	2013-08-15	Kowa Co., Ltd.	Prophylactic and/or therapeutic agent against lymphedema
WO2012058210A1 (fr)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr)	2010-12-21	2012-06-28	Schering Corporation	Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
EP2675440B1 (fr)	2011-02-14	2020-03-25	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine protéases, les cathepsines
WO2012141160A1 (fr)	2011-04-12	2012-10-18	沢井製薬株式会社	Préparation contenant de la pitavastatine et son procédé de production
WO2012143879A1 (fr)	2011-04-21	2012-10-26	Piramal Healthcare Limited	Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
WO2012153181A1 (fr) *	2011-05-11	2012-11-15	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Composition pharmaceutique comprenant de la pitavastatine ou ses sels pharmaceutiquement acceptables
KR101830977B1 (ko) *	2011-06-30	2018-02-21	한미약품 주식회사	오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
EP2770987B1 (fr)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Nouveaux composés qui sont des inhibiteurs d'erk
WO2013086443A1 (fr)	2011-12-08	2013-06-13	Amgen Inc.	Protéines agonistes de liaison à l'antigène lcat humain et leur utilisation thérapeutique
EP3919620A1 (fr)	2012-05-02	2021-12-08	Sirna Therapeutics, Inc.	Compositions d'acide nucléique interférent court (sina)
WO2014022195A1 (fr)	2012-08-01	2014-02-06	Tavakoli Zahra	Compositions congelées à écoulement libre comprenant un agent thérapeutique
JP5190159B1 (ja)	2012-08-08	2013-04-24	興和株式会社	医薬
CA2882950A1 (fr)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Nouveaux composes inhibiteurs de erk
SMT201700595T1 (it)	2012-11-28	2018-03-08	Merck Sharp & Dohme	Composizioni e metodi per trattare il cancro
WO2014100065A1 (fr)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
CN110575445B (zh)	2013-03-21	2023-08-18	优普顺药物公司美国分部	可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
CN104069502B (zh) *	2013-03-29	2018-02-16	北京罗诺强施医药技术研发中心有限公司	复合骨架材料及其药物组合物
RO129060B1 (ro) *	2013-04-25	2014-11-28	Antibiotice S.A.	Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
KR101597004B1 (ko)	2013-07-25	2016-02-23	씨제이헬스케어 주식회사	서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2015034925A1 (fr)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Polynucléotides circulaires
RU2692799C2 (ru)	2013-10-08	2019-06-27	Мерк Шарп И Доум Корп.	Ингибиторы цистеинпротеаз катепсинов
WO2015051479A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine-protéases de type cathepsines
GB201319791D0 (en) *	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
EP3613418A1 (fr)	2014-01-17	2020-02-26	Ligand Pharmaceuticals, Inc.	Procédés et compositions de modulation des niveaux d'hormones
WO2015120580A1 (fr)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Inhibiteurs de protéases à cystéine de type cathépsines
WO2015185240A1 (fr)	2014-06-04	2015-12-10	Sigma-Tau Industrire Farmaceutiche Riunite S.P.A.	Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
KR20170083071A (ko)	2014-11-11	2017-07-17	시오노기 앤드 컴파니, 리미티드	광에 대해서 불안정한 약물을 함유하는 다층 정제
AU2016343952A1 (en)	2015-10-27	2018-05-10	Eupraxia Pharmaceuticals Inc.	Sustained release formulations of local anesthetics
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
RU2648445C1 (ru) *	2016-11-03	2018-03-26	Светлана Асылхановна Астафьева	6-(3,3- диметил-3,4-дигидроизохинолин-1-ил) аминогексановая кислота и фармацевтическая композиция на ёе основе, обладающие анальгетической активностью
WO2019094312A1 (fr)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
EP3706742B1 (fr)	2017-11-08	2023-03-15	Merck Sharp & Dohme LLC	Inhibiteurs de prmt5
KR101954568B1 (ko) *	2018-01-22	2019-03-05	한미약품 주식회사	오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
WO2020033282A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
WO2020033285A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
CA3108388A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
EP3833667B1 (fr)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Inhibiteurs de prmt5
AU2020257397B2 (en)	2019-04-19	2026-02-26	Ligand Pharmaceuticals Inc.	Crystalline forms and methods of producing crystalline forms of a compound
ES3022307T3 (en)	2019-12-17	2025-05-28	Merck Sharp & Dohme Llc	Prmt5 inhibitors
ES3074517T3 (en)	2019-12-17	2026-07-21	Merck Sharp & Dohme Llc	4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4076459B1 (fr)	2019-12-17	2026-04-29	Merck Sharp & Dohme LLC	Inhibiteurs de prmt5
EP4076460B1 (fr)	2019-12-17	2026-01-21	Merck Sharp & Dohme LLC	Dérivés de 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine] en tant qu'inhibiteurs de prmt5 pour le traitement du cancer
WO2024180169A1 (fr)	2023-03-02	2024-09-06	Carcimun Biotech Gmbh	Moyens et procédés de diagnostic du cancer et/ou d'une maladie inflammatoire aiguë
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3865935A (en) *	1972-08-10	1975-02-11	Abbott Lab	Tableting of erythromycin base
US3952096A (en) *	1973-06-15	1976-04-20	Bristol-Myers Company	Mixture of calcium carbonate and calcium-α-p-chlorophenoxyisobutyrate as an antihyperlipemic agent
US3891755A (en) *	1973-07-11	1975-06-24	Abbott Lab	Dosage formulation for erythromycin cetyl sulfate
US4342767A (en) *	1980-01-23	1982-08-03	Merck & Co., Inc.	Hypocholesteremic fermentation products
HU204253B (en) *	1982-11-22	1991-12-30	Sandoz Ag	Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4739073A (en) *	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4744987A (en) *	1985-03-08	1988-05-17	Fmc Corporation	Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4671953A (en) *	1985-05-01	1987-06-09	University Of Utah Research Foundation	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
DE3524572A1 (de) *	1985-07-10	1987-01-15	Thomae Gmbh Dr K	Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
CA1327010C (fr) *	1986-02-13	1994-02-15	Tadashi Makino	Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
GB2189699A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
US4929605A (en) *	1987-10-07	1990-05-29	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol derivatives
US5030447A (en) *	1988-03-31	1991-07-09	E. R. Squibb & Sons, Inc.	Pharmaceutical compositions having good stability
US4997658A (en) *	1988-11-21	1991-03-05	Merck & Co., Inc.	Method for enhancing the lowering of plasma cholesterol levels
US4933165A (en) *	1989-01-18	1990-06-12	Merck & Co., Inc.	Coenzyme Q10 with HMG-CoA reductase inhibitors
US5004651A (en) *	1989-01-24	1991-04-02	Abbott Laboratories	Stabilizing system for solid dosage forms
CA2016467A1 (fr) *	1989-06-05	1990-12-05	Martin Eisman	Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
CA2042526A1 (fr) *	1990-06-11	1991-12-12	Adeoye Y. Olukotun	Methode permettant de prevenir une deuxieme crise cardiaque a l'aide d'un inhibiteur de la hmg coa-reductase

1992
- 1992-11-30 HU HU9203780A patent/HU9203780D0/hu unknown
- 1992-11-30 HU HU9203780A patent/HU217629B/hu unknown
- 1992-12-02 DE DE4240430A patent/DE4240430B4/de not_active Expired - Lifetime
- 1992-12-04 IT ITRM920870A patent/IT1256698B/it active IP Right Grant
- 1992-12-07 CH CH3751/92A patent/CH684309A5/de not_active IP Right Cessation
- 1992-12-08 DK DK92810962T patent/DK0547000T3/da active
- 1992-12-08 EP EP92810962A patent/EP0547000B1/fr not_active Expired - Lifetime
- 1992-12-08 ES ES92810962T patent/ES2142819T3/es not_active Expired - Lifetime
- 1992-12-08 PT PT92810962T patent/PT547000E/pt unknown
- 1992-12-08 GB GB9225659A patent/GB2262229B/en not_active Expired - Lifetime
- 1992-12-10 FI FI925615A patent/FI114284B/fi not_active IP Right Cessation
- 1992-12-10 NO NO924768A patent/NO302099B1/no not_active IP Right Cessation
- 1992-12-10 AU AU30069/92A patent/AU661075B2/en not_active Expired
- 1992-12-10 NZ NZ245421A patent/NZ245421A/en unknown
- 1992-12-10 JP JP4352222A patent/JP2774037B2/ja not_active Expired - Lifetime
- 1992-12-10 RO RO92-01545A patent/RO111542B1/ro unknown
- 1992-12-10 SK SK3633-92A patent/SK281710B6/sk not_active IP Right Cessation
- 1992-12-10 CA CA002085037A patent/CA2085037C/fr not_active Expired - Lifetime
- 1992-12-10 KR KR1019920023818A patent/KR100253824B1/ko not_active Expired - Lifetime
- 1992-12-10 IL IL10404192A patent/IL104041A/en not_active IP Right Cessation
- 1992-12-10 MX MX9207152A patent/MX9207152A/es unknown
- 1992-12-10 CZ CS19923633A patent/CZ287776B6/cs not_active IP Right Cessation
- 1992-12-11 ZA ZA929642A patent/ZA929642B/xx unknown
- 1992-12-11 AT AT0244992A patent/AT401870B/de not_active IP Right Cessation
- 1992-12-11 RU RU92004564A patent/RU2121835C1/ru active
- 1992-12-11 LU LU88201A patent/LU88201A1/fr unknown
- 1992-12-14 FR FR9215142A patent/FR2684876B1/fr not_active Expired - Lifetime
- 1992-12-22 US US07/995,252 patent/US5356896A/en not_active Expired - Lifetime
1993
- 1993-01-30 CN CN93100650A patent/CN1041794C/zh not_active Expired - Lifetime
1997
- 1997-03-06 HK HK25597A patent/HK25597A/xx not_active IP Right Cessation
- 1997-09-05 CY CY199497A patent/CY1994A/en unknown
2000
- 2000-03-10 GR GR20000400625T patent/GR3032929T3/el unknown

Also Published As

Publication number	Publication date
FI925615A0 (fi)	1992-12-10
EP0547000A1 (fr)	1993-06-16
AU3006992A (en)	1993-06-17
EP0547000B1 (fr)	2000-02-02
JP2774037B2 (ja)	1998-07-09
CZ363392A3 (en)	1993-09-15
GR3032929T3 (en)	2000-07-31
CN1041794C (zh)	1999-01-27
NO924768D0 (no)	1992-12-10
RO111542B1 (ro)	1996-11-29
RU2121835C1 (ru)	1998-11-20
HUT63328A (en)	1993-08-30
IL104041A0 (en)	1993-05-13
FR2684876A1 (fr)	1993-06-18
GB2262229B (en)	1995-11-01
JPH05246844A (ja)	1993-09-24
PT547000E (pt)	2000-06-30
CH684309A5 (de)	1994-08-31
NO302099B1 (no)	1998-01-26
SK281710B6 (sk)	2001-07-10
HU9203780D0 (en)	1993-03-29
CZ287776B6 (cs)	2001-01-17
ES2142819T3 (es)	2000-05-01
FI114284B (fi)	2004-09-30
ATA244992A (de)	1996-05-15
FI925615L (fi)	1993-06-13
MX9207152A (es)	1993-07-01
GB9225659D0 (en)	1993-01-27
ITRM920870A1 (it)	1994-06-04
US5356896A (en)	1994-10-18
AT401870B (de)	1996-12-27
LU88201A1 (fr)	1994-09-09
DK0547000T3 (da)	2000-06-26
IT1256698B (it)	1995-12-12
CN1091634A (zh)	1994-09-07
AU661075B2 (en)	1995-07-13
KR100253824B1 (ko)	2000-05-01
NZ245421A (en)	1995-11-27
NO924768L (no)	1993-06-14
GB2262229A (en)	1993-06-16
CY1994A (en)	1997-09-05
DE4240430B4 (de)	2007-12-27
HU217629B (hu)	2000-03-28
CA2085037C (fr)	2000-11-28
ITRM920870A0 (it)	1992-12-04
DE4240430A1 (fr)	1993-06-17
ZA929642B (en)	1994-06-13
SK363392A3 (en)	1994-11-09
HK25597A (en)	1997-03-06
CA2085037A1 (fr)	1993-06-13
FR2684876B1 (fr)	1995-05-05

Legal Events

Date	Code	Title
1999-06-20	FF	Patent granted
2000-02-17	KB	Patent renewed
2003-02-12	KB	Patent renewed
2007-02-12	KB	Patent renewed
2010-12-30	KB	Patent renewed
2013-07-31	EXP	Patent expired

Publication	Publication Date	Title
EP0547000B1 (fr)	2000-02-02	Compositions stabilisées contenant des inhibiteurs de réductase de HMG-CoA
US20070202159A1 (en)	2007-08-30	Pharmaceutical composition comprising stabilized statin particles
KR100421347B1 (ko)	2004-03-06	약학 혼합 제제
US20050239884A1 (en)	2005-10-27	Compositions comprising hmg-coa reductase inhibitor
US20070218134A1 (en)	2007-09-20	Compositions Comprising Organic Compounds
WO2003000177A2 (fr)	2003-01-03	Compositions pharmaceutiques a liberation controlee, stables, contenant de la pravastatine
NZ270729A (en)	1995-11-27	Fluvastatin sodium in an alkaline carrier
AU734787B2 (en)	2001-06-21	Method for producing medicaments containing HMG-CoA-reductase inhibitors
US20040180087A1 (en)	2004-09-16	Stable controlled release pharmaceutical compositions containing pravastatin
US20190070167A1 (en)	2019-03-07	Pitavastatin containing preparation and method for producing same
AU2002312297A1 (en)	2003-01-08	Stable controlled release pharmaceutical compositions containing pravastatin